High Prevalence of Advanced Liver Fibrosis Assessed by Transient Elastography Among U.S. Adults With Type 2 Diabetes
- PMID: 33303638
- DOI: 10.2337/dc20-1778
High Prevalence of Advanced Liver Fibrosis Assessed by Transient Elastography Among U.S. Adults With Type 2 Diabetes
Abstract
Objective: Type 2 diabetes mellitus (T2DM) is an important risk factor for the progression of metabolic liver disease to advanced fibrosis. Here, we provide an estimate of the prevalence of steatosis and fibrosis in U.S. adults with T2DM on the basis of transient elastography (TE) and identify factors associated with these conditions.
Research design and methods: This is a cross-sectional study of U.S. adults with T2DM participating in the 2017-2018 cycle of the National Health and Nutrition Examination Survey who were evaluated by TE. Hepatic steatosis and fibrosis were diagnosed by the median value of controlled attenuation parameter (CAP) and liver stiffness measurement (LSM), respectively.
Results: Among the 825 patients with reliable TE examination results, 484 (53.7%) were assessed using the M probe and 341 (46.3%) using the XL probe. Liver steatosis (CAP ≥274 dB/m), advanced fibrosis (LSM ≥9.7 kPa), and cirrhosis (LSM ≥13.6 kPa) were present in 73.8% (95% CI 68.5%-78.5%), 15.4% (95% CI 12.2%-19.0%), and 7.7% (95% CI 4.8%-11.9%) of patients, respectively. The mean ± SE age of patients with advanced fibrosis and cirrhosis was 63.7 ± 2.2 years and 57.8 ± 1.6 years, respectively. In the multivariable logistic regression model, BMI, non-Black race, and ALT levels were independent predictors of steatosis; and BMI, non-Black race, and AST and γ-glutamyltranspeptidase levels were independent predictors of advanced fibrosis.
Conclusions: Prevalence of both liver steatosis and fibrosis is high in patients with T2DM from the United States and obesity is a major risk factor. Our results support the screening of these conditions among patients with diabetes.
© 2020 by the American Diabetes Association.
Similar articles
-
Screening for hepatic fibrosis and steatosis in Turkish patients with type 2 diabetes mellitus: A transient elastography study.Turk J Gastroenterol. 2019 Mar;30(3):266-270. doi: 10.5152/tjg.2018.18559. Turk J Gastroenterol. 2019. PMID: 30411703 Free PMC article.
-
Screening for non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus using transient elastography.J Gastroenterol Hepatol. 2019 Aug;34(8):1396-1403. doi: 10.1111/jgh.14577. Epub 2019 Jan 21. J Gastroenterol Hepatol. 2019. PMID: 30551263
-
Blood pressure, glycemic status and advanced liver fibrosis assessed by transient elastography in the general United States population.J Hypertens. 2021 Aug 1;39(8):1621-1627. doi: 10.1097/HJH.0000000000002835. J Hypertens. 2021. PMID: 33657584 Free PMC article.
-
When the liver gets stiff, the tough get moving.J Gastroenterol Hepatol. 2020 Jun;35(6):953-959. doi: 10.1111/jgh.14963. Epub 2020 Feb 11. J Gastroenterol Hepatol. 2020. PMID: 31867782 Review.
-
Surveillance of the liver in type 2 diabetes: important but unfeasible?Diabetologia. 2024 Jun;67(6):961-973. doi: 10.1007/s00125-024-06087-7. Epub 2024 Feb 9. Diabetologia. 2024. PMID: 38334817 Free PMC article. Review.
Cited by
-
Elevated non-HDL-C to HDL-C ratio as a marker for NAFLD and liver fibrosis risk: a cross-sectional analysis.Front Endocrinol (Lausanne). 2024 Oct 15;15:1457589. doi: 10.3389/fendo.2024.1457589. eCollection 2024. Front Endocrinol (Lausanne). 2024. PMID: 39473504 Free PMC article.
-
Pharmacological Approaches to Nonalcoholic Fatty Liver Disease: Current and Future Therapies.Diabetes Spectr. 2024 Winter;37(1):48-58. doi: 10.2337/dsi23-0012. Epub 2024 Feb 15. Diabetes Spectr. 2024. PMID: 38385098 Free PMC article.
-
Monocyte-to-High-Density Lipoprotein-Cholesterol Ratio Predicts Prognosis of Hepatocellular Carcinoma in Patients with Metabolic-Associated Fatty Liver Disease.J Hepatocell Carcinoma. 2024 Jan 18;11:145-157. doi: 10.2147/JHC.S439397. eCollection 2024. J Hepatocell Carcinoma. 2024. PMID: 38260867 Free PMC article.
-
4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes-2024.Diabetes Care. 2024 Jan 1;47(Suppl 1):S52-S76. doi: 10.2337/dc24-S004. Diabetes Care. 2024. PMID: 38078591 Free PMC article. Review.
-
Identifying advanced MAFLD in a cohort of T2DM and clinical features.Front Endocrinol (Lausanne). 2023 Feb 22;14:1058995. doi: 10.3389/fendo.2023.1058995. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 36909342 Free PMC article.
MeSH terms
Associated data
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous